Relationships between aminoglycoside and vancomycin pharmacokinetics in patients with hematopoietic stem-cell transplants

American Journal of Health-System Pharmacy

Volumn 56, Issue 2, 1999, Pages 161-164

  Leader, W Greg ^a   Andria, Michael ^b   Kessel, Kellie K ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b Box 9520 ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0033556118     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.2.161     Document Type: Article

References (18)

1. Part MD, Messino MJ, McIntyre W. Allogeneic bone marrow transplantation: procedures and complications. Am J Hosp Pharm. 1991; 48:127-37.
2. Del Mar Fernández de Gatta M, Fruns I, Hernández JM et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm. 1993; 12:515-20.
3. Hary L, Andrejak M, Bernaert FR et al. Pharmacokinetics of amikacin in febrile neutropenic patients. Curr Ther Res. 1989; 46:821-7.
4. Higa GM, Murray WE. Alteration in aminoglycoside pharmacokinetics in patients with cancer. Clin Pharm. 1987; 6:963-6.
5. Zeitany RG, Saghir NE, Santhosh-Kumar CR et al. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother. 1990; 34:702-8.
6. Kaojaren S, Maoleekoonpairoj S, Atichartakarn V. Pharmacokinetics of amikacin in hematologic malignancies. Antimicrob Agents Chemother. 1989; 33:1406-8.
7. Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986; 11:257-82.
8. Pechere JC, Dugal R. Clinical pharmacokinetics of aminoglycoside antibiotics. Clin Pharmacokinet. 1979; 4:170-99.
9. Welch LP, Leader WG, Chandler MHH. Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics. Clin Pharm. 1993; 12:909-13.
10. Wragge TM, Cooper BE. Correlation of aminoglycoside and vancomycin pharmacokinetic parameters. Ann Pharmacother. 1993; 27:1346-8.
11. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1975; 4:183-95.
12. Snedecor GW, Corcoran WG. Statistical methods. 7th ed. Ames, IA: Iowa State Univ. Press; 1980.
13. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981; 2:93-113.
14. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet. 1995; 28:327-42.
15. Soto J, Alsar MJ, Chantal P et al. Correlation of vancomycin clearance and creatinine clearance: unreliability for predicting initial dosing in neutropenic hematological patients. J Antimicrob Chemother. 1993; 32:920-2. Letter.
16. Anne L, Hu M, Chan K et al. Potential problem with fluorescence polarization immunoassay cross reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit. 1989; 11:585-91.
17. Morse GD, Nair'n DK, Bertino JS et al. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit. 1987; 9:212-5.
18. Ackerman BH, Olsen KM, Padilla CB. Errors in assuming a one-compartment model for vancomycin. Ther Drug Monit. 1990; 12:304-5. Letter.